Market Research Logo

Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Revie

Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Review, H1 2016’, provides in depth analysis on Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted pipeline therapeutics.

The report provides comprehensive information on the Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2)
  • The report reviews Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) Overview
Therapeutics Development
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Stage of Development
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Therapy Area
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Indication
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Unknown Stage Products
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Companies
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Products under Development by Universities/Institutes
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Companies Involved in Therapeutics Development
Connexios Life Sciences Pvt. Ltd.
CymaBay Therapeutics, Inc.
Genfit SA
GlaxoSmithKline Plc
Inventiva
Mitobridge, Inc.
Nippon Chemiphar Co., Ltd.
Plexxikon Inc.
T3D Therapeutics, Inc.
vTv Therapeutics LLC
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Drug Profiles
CNX-013B2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-610742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HPP-593 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IVA-337 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MBX-8025 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Pan PPAR for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PPAR Beta and PPAR Delta for Metabolic Disorders, Inflammatory Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target PPAR delta for Mitochondrial Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T3D-959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Dormant Projects
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Discontinued Products
Peroxisome Proliferator-Activated Receptor Delta (PPAR-Delta or NUCI or Nuclear Hormone Receptor 1 or NUC1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator-Activated Receptor Beta or PPAR-Beta or PPARD or NR1C2) - Featured News & Press Releases
Mar 31, 2016: GENFIT to Begin Elafibranor Clinical Program in PBC
Mar 30, 2016: Presentations at EASL/ILC 2016 Highlight Progress in NASH Treatment, Biomarker Diagnostics, and Programs Targeting Fibrotic Diseases
Mar 17, 2016: CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia
Mar 10, 2016: GENFIT announces enrollment of first patient in RESOLVE-IT, the pivotal Phase 3 clinical trial of Elafibranor in NASH
Feb 25, 2016: Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress
Feb 11, 2016: Data from phase 2b trial of Genfit elafibranor published in Gastroenterology
Jan 28, 2016: IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge
Nov 16, 2015: GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input
Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis
Jun 22, 2015: T3D Therapeutics Receives FDA IND Approval to Begin Phase 2 Clinical Study of T3D-959 in Alzheimer's Patients
Jun 08, 2015: T3D Therapeutics Selected by the Alzheimer’s Association to Present Pre-Clinical Results of T3D-959 at the 2015 Alzheimer’s Association International Conference
Apr 24, 2015: New Proof Of Efficacy Of Gft505 In Nash And Positive Expert Opinion
Apr 23, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia
Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
Mar 26, 2015: Genfit Announces Topline Results From The Golden-505 Trial In Nash
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016
Pipeline by CymaBay Therapeutics, Inc., H1 2016
Pipeline by Genfit SA, H1 2016
Pipeline by GlaxoSmithKline Plc, H1 2016
Pipeline by Inventiva, H1 2016
Pipeline by Mitobridge, Inc., H1 2016
Pipeline by Nippon Chemiphar Co., Ltd., H1 2016
Pipeline by Plexxikon Inc., H1 2016
Pipeline by T3D Therapeutics, Inc., H1 2016
Pipeline by vTv Therapeutics LLC, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Dormant Projects (Contd..2), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report